Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.45 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27537771 | 0.91 | TSHR (0.54) | LMNAALDH1A1CYP4F2CYP4A11TSHR | |
| SCHEMBL3033016 | 0.89 | LMNA (0.66) | LMNAALDH1A1CYP4F2CYP4A11TSHR | |
| SCHEMBL1198044 | 0.87 | CYP4F2 (0.66) | LMNAALDH1A1CYP4F2CYP4A11TSHR | |
| SCHEMBL15344632 | 0.86 | LMNA (0.62) | LMNAALDH1A1CYP4F2CYP4A11TSHR | |
| SCHEMBL27425790 | 0.85 | LMNA (0.57) | LMNAALDH1A1CYP4F2CYP4A11TSHR | |
| SCHEMBL111664 | 0.85 | LMNA (0.75) | LMNAALDH1A1TSHRESR1CHRM1 | |
| SCHEMBL27626642 | 0.84 | SLC7A5 (0.47) | LMNAALDH1A1CYP4F2CYP4A11TSHR | |
| SCHEMBL11599440 | 0.84 | LMNA (0.60) | LMNAALDH1A1CYP4F2CYP4A11TSHR | |
| SCHEMBL31346674 | 0.84 | LMNA (0.60) | LMNAALDH1A1CYP4F2CYP4A11TSHR | |
| SCHEMBL3813671 | 0.84 | LMNA (0.60) | LMNAALDH1A1CYP4F2CYP4A11TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054680-A1 | Agonists and antagonists of 5h3-like receptors of invertebrates as pesticides | COMMONWEALTH SCIENTIFIC INDUSTRIAL RESEARCH ORGANISATION (AU) | 2005-03-10 | — | — | US | disclosed |
| US-5700938-A | Intermediates for imidazopyridine derivatives | EISAI CO., LTD. (JP) | 1997-12-23 | — | — | US | disclosed |
| US-5618969-A | Intermediates for imidazopyridines | EISAI CO., LTD. (JP) | 1997-04-08 | — | — | US | disclosed |
| US-5608068-A | Process for the preparation of imidazopyridine derivatives and intermediates | EISAI CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| US-5587504-A | Sulfonyloxy-biphenylcarboxylic ester derivatives which are intermediates | EISAI CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5583229-A | Process for the preparation of imidazopyridine derivatives | EISAI CO., LTD. (JP) | 1996-12-10 | — | — | US | disclosed |
| US-5559236-A | Intermediates for substituted biphenylmethylmidazopyridine angiotensin II antagonists | EISAI CO., LTD. (JP) | 1996-09-24 | — | — | US | disclosed |
| US-5557002-A | Process for the preparation of biphenyl containing intermediates useful in making angiotensin II receptor antagonists | EISAI CO., LTD. (JP) | 1996-09-17 | — | — | US | disclosed |
| US-5554757-A | Process for the preparation of imidazopyridine derivatives, and intermediates therefore | EISAI CO., LTD. (JP) | 1996-09-10 | — | — | US | disclosed |
| EP-0627433-A1 | PROCESS FOR PRODUCING IMIDAZOPYRIDINE DERIVATIVE AND INTERMEDIATE | Eisai Co., Ltd. (JP) | 1994-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054680-A1 | Agonists and antagonists of 5h3-like receptors of invertebrates as pesticides | HTR3C, HTR3A, HTR3E | LMNA 3642/4885ALDH1A1 1565/4885CYP4F2 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.